CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing

Abstract Background Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to date. Whereas unilateral intraocular retinoblastoma is cured by enucle...

Full description

Bibliographic Details
Main Authors: Lena Andersch, Josefine Radke, Anika Klaus, Silke Schwiebert, Annika Winkler, Elisa Schumann, Laura Grunewald, Felix Zirngibl, Carina Flemmig, Michael C. Jensen, Claudia Rossig, Antonia Joussen, Anton Henssen, Angelika Eggert, Johannes H. Schulte, Annette Künkele
Format: Article
Language:English
Published: BMC 2019-09-01
Series:BMC Cancer
Subjects:
Adoptive T-cell immunotherapy
Retinoblastoma
CD171
GD2
Antigen loss
Sequential CAR-T cell therapy
Online Access:http://link.springer.com/article/10.1186/s12885-019-6131-1

Internet

http://link.springer.com/article/10.1186/s12885-019-6131-1

Similar Items